Summary
Medtronic plc announced a change to its Board of Directors, effective June 27, 2022. The size of the Board has been increased from 10 to 11 members, and Lidia L. Fonseca has been appointed as a new director. This appointment is a standard governance update, bringing new expertise to the company's leadership. Investors should note that Ms. Fonseca will participate in the company's standard director compensation plan, including cash retainers and equity grants. Her appointment to key committees, Science and Technology and Compensation, suggests a focus on innovation and executive remuneration oversight.
Key Highlights
- 1Medtronic plc's Board of Directors size increased from 10 to 11 members.
- 2Lidia L. Fonseca appointed as a new director, effective June 27, 2022.
- 3Ms. Fonseca appointed to the Science and Technology Committee.
- 4Ms. Fonseca appointed to the Compensation Committee.
- 5Ms. Fonseca will receive standard non-employee director compensation (cash retainer and equity grant).
- 6No undisclosed arrangements or reportable transactions between Ms. Fonseca and Medtronic.
Frequently Asked Questions
The provided filing does not detail Lidia L. Fonseca's specific professional background. However, her appointment to the Science and Technology and Compensation committees suggests relevant expertise in these areas. Investors may refer to the press release (Exhibit 99.1) or Medtronic's proxy statement for more comprehensive biographical information.
Increasing the Board size to accommodate a new director is a common governance practice, often done to add specific expertise or to manage workload across committees. In this case, it allows for the integration of Ms. Fonseca's contributions to the Board's oversight functions.
Ms. Fonseca will be compensated according to Medtronic's non-employee director compensation policy, which includes an annual cash retainer and a director equity grant. The specifics of this compensation are detailed in the company's Definitive Proxy Statement filed on October 8, 2021.
The filing explicitly states that there were no arrangements between Ms. Fonseca and any other persons for her selection, and she has not been involved in any reportable transactions with the company. This indicates a standard and clean appointment process.